Strides Pharma Science on Tuesday said its profit after tax increased 81% year-on-year to ₹114 crore for the first quarter ended June 30, 2025.
The company reported a profit after tax (PAT) of ₹63 crore for the April-June period of last year.
Revenue rose to ₹1,120 crore for the June quarter against ₹1,054 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.
31 October 2025
Get the latest issue of Outlook Business
"Our focus on cost management and diligent execution has enabled us to deliver robust results," Strides Pharma Science MD & Group CEO Badree Komandur said.
The company will enhance its R&D efforts during the year to drive sustainable long-term growth, he added.
Shares of Strides Pharma were trading 4.71% higher at ₹965.95 apiece on the BSE.
